Methadone prescribing and administration in pregnancy. by unknown
CLINICAL PRACTICE GUIDELINE          METHADONE PRESCRIBING AND ADMINISTRATION IN 
PREGNANCY 
 
 1 
 
 
 
 
 
CLINICAL PRACTICE GUIDELINE 
 
 
 
METHADONE PRESCRIBING AND ADMINISTRATION 
IN PREGNANCY 
 
 
 
 
Institute of Obstetricians and Gynaecologists, 
Royal College of Physicians of Ireland 
And 
Directorate of Strategy and Clinical Care 
     Health Service Executive 
 
 
 
 
 
 
 
 
 
 
 
Version 1.0    Date of publication: April 2013 
Guideline No.21   Revision date: April 2015 
CLINICAL PRACTICE GUIDELINE          METHADONE PRESCRIBING AND ADMINISTRATION IN 
PREGNANCY 
 
 2 
Table of Contents 
 
 Key Recommendations ........................................................... 3 
1. Purpose and Scope ................................................................. 4 
2. Background and Introduction .................................................. 4 
3. Methodology ......................................................................... 5 
4. Clinical Guideline ................................................................... 6 
4.1 Clinical Scenario 1 .................................................................. 7 
4.2 Clinical Scenario 2. ................................................................. 8 
4.3 Clinical Scenario 3 .................................................................. 9 
4.4   Clinical Scenario 4 ................................................................ 11 
4.5 Intoxicated Pregnant women ................................................. 12 
4.6 Vomiting in pregnant women on methadone-maintenance ........ 12 
4.7 Discharge of methadone- maintained women .......................... 13 
4.8 Peripartum pain management................................................ 14 
4.9 Breastfeeding ...................................................................... 15 
4.10 Methadone dosing in pregnancy ............................................. 16 
5. Hospital Equipment and Facilities ........................................... 17 
6. Implementation Strategy ...................................................... 17 
7. Key Performance Indicators................................................... 17 
8. Qualifying Statement ............................................................ 17 
9. Appendices ......................................................................... 18 
9.1 Appendix 1- Treatment of Suspected Opiate Overdose.............. 18 
9.2 Appendix 2- Inpatient Methadone Record Sheet ....................... 19 
9.3 Appendix 3- Clinical Opiate Withdrawal Scal ............................ 20 
9.4 Appendix 4- Addiction Services Contact Details ........................ 21 
10. References .......................................................................... 22 
 
  
CLINICAL PRACTICE GUIDELINE          METHADONE PRESCRIBING AND ADMINISTRATION IN 
PREGNANCY 
 
 3 
Key Recommendations 
1. Methadone maintenance treatment is the treatment of choice for opioid-
dependent pregnant women. In adequate doses, methadone provides 
stability for the woman during pregnancy, avoiding repeated cycles of 
intoxication and withdrawal that may adversely affect the fetus. 
 
2. Withdrawal from opioids can cause fetal death and preterm delivery. It is 
important that women who report illicit opiate use are assessed and treated 
in a timely manner. 
 
3. Clear communication between Maternity Hospitals and local Addiction 
Services is required, particularly in relation to methadone doses and 
admission/discharge of methadone-maintained women. 
 
4. Initiation of methadone may be required in a Maternity Hospital to avoid 
obstetric complications of opioid withdrawal. Careful initiation is required, as 
the highest risk of overdose mortality is in the first two weeks on methadone 
treatment. 
 
5. A validated scoring tool should be used to assess signs of opioid withdrawal 
in opioid-dependent pregnant women. 
 
6. Opioid-dependent pregnant women are at risk of under-treatment of 
peripartum pain. 
 
7. Breastfeeding should be encouraged in women who are stable on methadone 
maintenance treatment unless there are other medical contraindications. 
 
8. The maternal methadone dose should be individually adjusted to control 
maternal craving or withdrawal symptoms. 
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1. Purpose and Scope 
The purpose of this guideline is to promote the safe and effective prescribing and 
administration of methadone in antenatal and postnatal opioid-dependent 
women. These guidelines are intended for healthcare professionals, particularly 
those in training, who are working in HSE-funded obstetric and gynaecological 
services. They are designed to guide clinical judgement but not replace it. In 
individual cases a healthcare professional may, after careful consideration, 
decide not to follow a guideline if it is deemed to be in the best interests of the 
woman.  
 
2. Background and Introduction 
This document provides guidance on the assessment of methadone-maintained 
women and women currently using illicit opioids. It addresses admission and 
discharge procedures in Maternity Hospitals, the prescribing and administration 
of methadone, the management of vomiting in women on methadone, 
peripartum pain management and breastfeeding in opioid-dependent women 
treated with methadone. 
 
Methadone is the first-line treatment for the management of opioid-dependent 
pregnant women, as recommended by UK, US and Australian clinical guidelines 
(Batki et al, 2005; New South Wales Dept of Health, 2006; Dept of Health UK, 
2007). Compared to on-going heroin use, methadone maintenance treatment in 
the context of multidisciplinary care including antenatal care, has been 
associated with improved perinatal outcomes including higher birth weights, 
fewer obstetric complications, less preterm birth and reduced neonatal 
morbidity(Jones et al, 2012). Methadone maintenance treatment provides 
stability for the woman during pregnancy, avoiding repeated cycles of 
intoxication and withdrawal that may adversely affect the fetus (Kaltenbach et 
al, 1998).  
 
Withdrawal from opioids can cause fetal death and preterm delivery 
(Kaltenbach et al, 1998). It is important that women who report illicit 
opiate use are assessed and treated in a timely manner. 
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3. Methodology 
Medline, EMBASE and the Cochrane Database of Systematic Reviews were 
searched using terms including pregnancy, opioid related disorders, opiate, 
abuse/addiction/dependence, methadone, neonatal abstinence syndrome and 
neonatal withdrawal. Relevant meta-analyses, systematic reviews, interventional 
and observational studies were reviewed. International clinical guidelines were 
reviewed from Australia, Canada, UK, USA and the World Health Organisation 
(SEE REFS). 
  
The principal guideline developer was Dr. Brian Cleary, Senior Pharmacist, 
Coombe Women and Infants University Hospital. This guideline was developed 
from a previous guideline developed for use in the three Dublin Maternity 
Hospitals in 2011. Initial drafts of this document were developed by Justin 
Gleeson, Deirdre Carmody, Victoire Hurley, Dr. Michael O‘Connell and Dr Brian 
Cleary in May 2010. The draft document was discussed at group meetings of 
representatives of the three Dublin Maternity Hospitals and the HSE Addiction 
Services on 23rd June and 29th November 2010 (including Deirdre Carmody, Dr. 
Brian Cleary, Dr. Maeve Eogan, Dr. Anne Frankish, Justin Gleeson, Dr. Shane 
Higgins, Victoire Hurley, Dr. Eamon Keenan, Dr. Michael O‘Connell, Dr. John 
O‘Connor and Dr. Brion Sweeney). Comments from the guideline development 
group were incorporated into a final draft which was circulated to the Drug and 
Therapeutics Committees of the relevant organisations in February 2011. The 
guidelines were also presented at a national meeting of healthcare professionals 
from all the maternity hospitals in Farmleigh House in October 2012. 
 
The guideline was peer-reviewed by Ms Victoire Hurley (Midwifery), Ms Deirdre 
Carmody (Midwifery), Dr Emma Kilgarriff (GP). 
 
Finally, the guideline was reviewed and endorsed by the Programme‘s Clinical 
Advisory Group and National Working Party. 
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4. Clinical Guideline 
Background 
 
Methadone is an opioid agonist used in maintenance treatment of opioid 
dependence which suppresses opioid craving when given in effective doses. It is 
a controlled drug with a high dependency potential and a low lethal dose. 
Methadone should normally be prescribed as a 1mg/mL solution. Methadone 
should not be given to any women showing signs of intoxication, especially when 
due to alcohol or other depressant drugs e.g. benzodiazepines. 
 
Most methadone-maintained patients admitted to hospital are known to the 
Addiction Services. Women are either treated in a methadone maintenance clinic 
or in primary care, where trained GPs prescribed methadone which is then 
dispensed by a nominated community pharmacy. Ideally, all women with opioid 
dependence should attend a specialised or high risk antenatal clinic. In maternity 
hospitals without a specialised clinic that deals with opioid-dependent women, a 
single clinic should be nominated to provide continuity of care.  
 
Symptoms and Signs of Overdose 
 
The symptoms and signs of overdose with methadone parallel those for other 
opioids, namely profound respiratory depression, pin-point pupils, hypotension, 
circulatory failure and pulmonary oedema, coma and death. Mydriasis (dilation 
of the pupil) may replace miosis (constriction of the pupil) as asphyxia 
intervenes. 
 
For information on the management of suspected overdose see 
Appendix 1 
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4.1 Clinical Scenario 1: Pregnant women admitted and 
known to be on prescribed methadone from medical 
record or verbal history 
 
4.1.1 Contact the methadone clinic, or, if the woman is attending a 
prescribing GP, contact the pharmacy from where the woman‘s 
methadone is dispensed and inform them of the woman‘s admission to 
hospital (contact numbers of the Addiction Services are available in 
Appendix 4 or in the Inpatient Methadone Record Sheet in the woman‘s 
chart). 
4.1.2 Confirm: woman‘s name, date of birth, prescribing methadone clinic or 
G.P, dose of methadone and when next the methadone is due to be 
dispensed. Refer to Guidance to Nurses and Midwives on Medication 
Management section 2- Transcription of Prescription/Telephone Orders 
(An Bord Altranais, 2007). 
4.1.3 Contact a member of the relevant medical team regarding the 
admission at the earliest opportunity to prescribe the woman‘s 
methadone. 
4.1.4 Methadone should be supplied in accordance with the Misuse of Drugs 
Act. Methadone should be administered in the ward office to ensure 
woman confidentiality. Two midwives or registered general nurses 
should supply and sign for methadone in the controlled drug register. 
4.1.5 On discharge from the hospital the discharging team or midwife should 
inform the methadone clinic/GP/pharmacy of the amount of methadone 
provided while the woman was admitted. See section 4.7 Discharge of 
methadone- maintained women for further detail. 
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4.2 Clinical Scenario 2: Pregnant women admitted with 
a „take–away‟ methadone supply. 
 
4.2.1 Women are either on daily supervised methadone or are dispensed 
unsupervised ‗take-away‘ doses. 
4.2.2 Women should be advised not to bring in their ‗take-away‘ methadone 
supply when they are being admitted to the hospital.  
4.2.3 Under no circumstances should any methadone be stored by the 
woman at the bedside or in the woman‘s locker for reasons of health 
and safety. 
4.2.4 Any supply of methadone brought in to the hospital by the woman 
which cannot be sent home should not be used and should be sent to 
the Pharmacy Department for destruction. 
4.2.5 If a woman does bring in her ‗take-away‘ methadone supply, the exact 
amount of methadone sent for destruction in the Hospital Pharmacy 
should be recorded in the Inpatient Methadone Record Sheet in her 
chart (see Appendix 2).  
4.2.6 Contact the methadone clinic, or, if the woman is attending a 
prescribing GP, contact the pharmacy from where the woman‘s 
methadone is dispensed and inform them of the woman‘s admission to 
hospital (contact numbers of the Addiction Services are available in 
Appendix 4 or in the Inpatient Methadone Record Sheet in the woman‘s 
chart). 
4.2.7 Confirm: woman‘s name, date of birth, prescribing methadone clinic or 
G.P., dose of methadone and when next the methadone is due to be 
dispensed. Refer to Guidance to Nurses and Midwives on Medication 
Management section 2- Transcription of Prescription/Telephone Orders.  
4.2.8 Contact a member of the relevant medical team regarding the 
admission at the earliest opportunity to prescribe the woman‘s 
methadone. 
4.2.9 Women might not take all the methadone prescribed to them, for 
various reasons, in one single dose and may be splitting their dose into 
two or three portions during the 24 hour period.  
4.2.10 On discharge from the hospital the discharging team or midwife should 
inform the methadone clinic/GP/pharmacy of the amount of methadone 
sent to the Hospital Pharmacy for destruction and the amount 
dispensed while the woman was admitted. (contact numbers of the 
Addiction Services are available in Appendix 4 or in the Inpatient 
Methadone Record Sheet in the woman‘s chart) 
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4.3 Clinical Scenario 3: Pregnant women admitted to 
hospital self-reporting heroin use but not registered 
with the addiction services or a prescribing GP 
 
4.3.1 Withdrawal from opioids can cause fetal death and preterm delivery. It 
is important that women who report illicit opiate use are assessed and 
treated in a timely manner. 
4.3.2 Where possible seek guidance on the initiation of methadone from local 
Addiction Services (contact numbers of the Addiction Services are 
available in Appendix 4). 
4.3.3 A member of the relevant medical team must be contacted regarding 
admission to organise inpatient care and ensure access to local 
Addiction Services on discharge. 
4.3.4 The prescriber must ascertain that a patient is opioid-dependent before 
prescribing methadone. If there is no evidence of opioid-dependence in 
the patient‘s hospital notes then caution is advised. The initial two 
weeks of treatment with methadone are associated with an increased 
risk of overdose mortality (Cousins et al, 2011). It is vitally important 
that the appropriate assessment, titration of doses and monitoring are 
performed during this period.  
4.3.5 Obtain the woman‘s consent for urine toxicology to confirm opioid use. 
4.3.6 Obtain a supervised urine sample. 
4.3.7 The sample should be tested using a point-of-care toxicology testing 
dipstick. 
4.3.8 For confirmation the urine sample should also be sent for drug 
toxicology testing before methadone is administered if possible. Do not 
delay initiation of methadone while awaiting results. 
4.3.9 Urine toxicology does not confirm dependence or opioid tolerance and 
should be used alongside clinical judgement. 
4.3.10 Carry out a physical examination, looking for injection site or track 
marks or abscesses. 
4.3.11 Ascertain the extent of the self-reported drug use, method of 
administration, drug used, for how long, and the quantity used daily (in 
grams or monetary terms). 
4.3.12 Observe the woman and assess for signs or symptoms of withdrawal 
with Clinical Opiate Withdrawal Scale- see Appendix 3). 
4.3.13 If methadone is warranted based on clinical judgement or if there is 
evidence of withdrawal prescribe methadone 20mg stat with 
subsequent observation for signs of intoxication 
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4.3.14 Assess with Clinical Opiate Withdrawal Scale before any further doses 
are administered- see Appendix 3. 
4.3.15 Prescribe an additional 10mg of methadone every 4 hours as needed for 
withdrawal symptoms (generally up to a total maximum dose of 40mg 
in the first 24 hours) (BNF, 2010; Seligman et al, 2008; Berghella et al, 
2003).  
4.3.16 Seek advice from local Addiction Services before administering any 
further methadone if the patient is still displaying signs of withdrawal 
after the third dose (40mg total). 
4.3.17 If at any point the woman becomes sedated, increase the frequency of 
observation and ensure no further methadone is administered until 
sedation is reversed. 
4.3.18 Women should be encouraged to remain on the ward for 60-120 
minutes after the dose for observation (peak levels are reached after 2-
3 hours). 
4.3.19 Women should be cautioned about the use of other drugs while on 
methadone. 
4.3.20 The day 2 methadone dose should be the total methadone dose 
administered in the first 24 hours. This should be prescribed as a once 
daily dose. 
4.3.21 Reassess the patient for further signs of withdrawal after the day 2 
dose. Further doses of 10mg may be administered at 4-6 hour intervals 
up to a total maximum dose on day 2 of 60mg. 
4.3.22 Steady state plasma levels are reached after about 7-10 days.  
4.3.23 All women starting on methadone must be informed of the risks of 
toxicity and overdose and the need for methadone maintenance as an 
outpatient if started on treatment in hospital. 
 
CLINICAL PRACTICE GUIDELINE          METHADONE PRESCRIBING AND ADMINISTRATION IN 
PREGNANCY 
 
 11 
4.4 Clinical Scenario 4: Pregnant women admitted 
looking for a prescribed dose of methadone out of 
hours and known to be on prescribed methadone 
from medical record or verbal history 
 
4.4.1 Withdrawal from opioids can cause fetal death and preterm delivery 
(Kaltenbach, 1998). It is important that women who report illicit opiate 
use are assessed and treated in a timely manner. 
4.4.2 In this unexpected situation the woman is admitted to hospital ‗out of 
hours‘ requesting a dose of methadone as she has missed her dose in 
the methadone clinic or pharmacy. As it is out of hours the dosage or 
dispensing details for that day cannot be confirmed with the dispensing 
clinic or pharmacy. 
4.4.3 Methadone should not be administered on an outpatient basis. The 
woman should be admitted for assessment. 
4.4.4 Before prescribing any methadone, the prescriber should assess the 
woman for opioid withdrawal using the Clinical Opiate Withdrawal Scale 
(Appendix 3). 
4.4.5 As methadone has a half-life of approximately 24 hours, caution needs 
to be exercised and up to a maximum of half the woman‘s current dose 
should be prescribed as the patient‘s clinic/pharmacy will likely be open 
before 36hrs since last dose. 
4.4.6 The woman will need observation for signs of withdrawal or signs of 
opiate toxicity (see section 5.3). 
4.4.7 Further management as per Clinical Scenario 1(see section 4.1). 
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4.5 Intoxicated pregnant women 
 
4.5.1 In most reviews of methadone-related deaths concurrent use of 
sedatives such as benzodiazepines and alcohol was found to play a 
contributory role. 
4.5.2 Intoxicated women must not be dispensed methadone until they have 
been medically assessed and found to be unimpaired. 
 
4.6 Vomiting in pregnant women on methadone-
maintenance treatment 
4.6.1 To minimise risk of vomiting methadone during pregnancy: 
 Discourage ingesting methadone on an empty stomach. 
 Encourage women to sip their dose slowly. 
 Consider splitting the dose or giving an anti-emetic before dosing if 
the dose of methadone appears to consistently cause vomiting. 
4.6.2 If a woman vomits constantly and not necessarily in relation to her 
dose of methadone, she should be assessed for other causes of 
vomiting e.g. hyperemesis gravidarum or urinary tract infection. 
4.6.3 In cases of persistent vomiting it may be useful to consider another 
brand of methadone, which the woman may find more tolerable. 
4.6.4 If a methadone dose is vomited by a woman:  
 Within 10 minutes of dosing: consider giving a repeat dose 
 Within 10-30 minutes of dosing: consider giving half a repeat dose 
 More than 30 minutes after dosing: consider giving half a repeat 
dose only if withdrawal occurs (see Clinical Opiate Withdrawal 
Scale- Appendix 3)  
 Consider if the entire dose is likely to have been vomited. 
4.6.5 Vomiting of a methadone dose may lead to maternal and fetal 
withdrawal. It is preferable that staff have observed the vomiting, but 
since it is unlikely that all stomach contents are expelled during a 
vomit, it is still difficult to be sure how much of the dose has been 
absorbed. Where there is doubt, every effort should be made for the 
woman to be reassessed by an experienced doctor 4 to 6 hours after 
vomiting the methadone administered, when the effects of methadone 
should be at their peak, to determine whether an additional small dose 
is required. 
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4.7 Discharge of methadone- maintained women 
 
4.7.1 Contact the methadone clinic or, if the woman is attending a prescribing 
GP for methadone, the pharmacy where the woman is dispensed her 
methadone (documented on the Inpatient Methadone Record Sheet in 
her chart) on the day of discharge and inform them of:  
i) the amount of methadone sent to the Hospital Pharmacy for 
destruction (if any) 
ii) the amount of methadone dispensed while the patient was admitted 
iii) any opioids administered while the woman was admitted  
(see the Inpatient Methadone Record Sheet in her chart- Appendix 2).  
4.7.2 Under no circumstances should women be discharged with supplies of 
methadone issued from hospital stock. 
4.7.3 Do not give women a discharge prescription for methadone or 
benzodiazepines.  
4.7.4 If a woman wishes to be discharged unexpectedly during a weekend 
then it should be explained that there is limited access to dispensing 
methadone clinics, prescribing community GP‘s and some pharmacies. 
The majority of community agencies dispensing methadone close on 
bank holidays and dispense sufficient quantities of methadone the day 
before the bank holiday 
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4.8 Peripartum pain management 
 
Background 
Opioid-dependent patients are at risk of under-treatment of acute pain (Mehta 
and Langford, 2009). This may be due to opioid tolerance, misperceptions about 
drug seeking behaviour and expectation of analgesic effects of maintenance 
methadone (Hoflich et al, 2012).  
 
4.8.1 Opioid-dependent pregnant women should be offered the same options 
for pain relief as any other woman in labour or the postpartum period 
(ACOG, 2012). Maintenance doses of methadone will not provide 
adequate pain relief to opioid-dependent women. 
4.8.2 Some patients may be concerned about the risk of relapse of illicit 
opioid use after use of opioid analgesics. Patients should be reassured 
that there is no evidence that analgesic use of opioids leads to relapse 
of illicit drug use (Mehta and Langford, 2009).  
4.8.3 In general, opioid-dependent women will require higher doses of opioids 
to achieve an equivalent analgesic effect compared with other patients.  
4.8.4 There should be an awareness of possible additive effects- the 
postpartum patient who receives opioid therapy in addition to 
methadone should be closely monitored for symptoms of over-sedation 
with subsequent dose adjustment if required 
4.8.5 If a patient is prescribed opioids besides methadone while in hospital, 
this should be recorded on the Inpatient Methadone Record Sheet in her 
chart. The Addiction Clinic or GP should be informed of this opioid use 
as it may affect the interpretation of subsequent urine toxicology 
testing. 
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4.9 Breastfeeding 
 
Background 
The issue of breastfeeding in women with a history of drug misuse can be 
clinically challenging (Jansson, 2009). International clinical guidelines from the 
USA, Canada, Australia and New Zealand encourage methadone-maintained 
women to breastfeed in the absence of contraindications. A 2001 review of the 
American Academy of Paediatrics guidance on medications and lactation 
classified methadone as ―usually compatible with breastfeeding‖. This is a 
change from a previous version of the guideline which recommended that it was 
only compatible with breastfeeding at maternal doses below 20 mg per day 
(Wilson, 1990).  
 
4.9.1 Breastfeeding should be encouraged in women who are stable on 
methadone maintenance treatment unless there are other medical 
contraindications (Lactmed. Methadone, 2012).  
4.9.2 Clinical judgement should be used in determining whether 
breastfeeding is appropriate for an individual woman and her baby. 
Contraindications to breastfeeding include: 
 HIV infection 
 Ongoing illicit drug use 
4.9.3 Minimal levels of methadone are found in breast milk regardless of 
dose. 
4.9.4 Breastfeeding may attenuate the severity of NAS and lead to earlier 
hospital discharge (Phillip et al, 2003; Dryden et al, 2008; Pritham et 
al, 2012).  
4.9.5 Abrupt weaning of breastfed infants of women on methadone 
maintenance can result in infant withdrawal symptoms. 
4.9.6 Diazepam and other commonly used benzodiazepines are excreted into 
the breast milk and have active metabolites. Accumulation may occur 
with repeated doses, leading to sedation, particularly in a newborn or 
preterm infant. 
4.9.7 Seek advice on the safety of other concomitantly prescribed medicines 
in breastfeeding.  
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4.10 Methadone dosing in pregnancy 
 
Background 
There have been conflicting findings on the relationship between the methadone 
dose and development of NAS since the earliest reports of gestational 
methadone use (Blinick, 1968; Reddy et al, 1971). A recent meta-analysis 
reported that there was no consistent statistically significant difference in the 
incidence of NAS with differing doses of methadone (Cleary et al, 2010). Women 
frequently request detoxification or dose reductions during pregnancy, in the 
hope of reducing the risk of NAS (Dept of Health, UK 2007). There is no 
compelling evidence to support the lowering of maternal methadone doses 
during pregnancy in the hope of avoiding NAS (Batki et al, 2005).  
The issue of appropriate methadone dosing during pregnancy is further 
complicated by pregnancy-associated pharmacokinetic changes. Plasma 
methadone concentrations have been shown to be lower during pregnancy than 
in the postpartum period (Pond et al, 1985). These differences may be due to 
physiological changes such as increased total body water, a larger tissue 
reservoir, enhanced hepatic, placental and fetal clearance of methadone during 
pregnancy or a reduction in the absorption of methadone after oral 
administration (Szeto et al, 1982; Swift et al, 1989; Jarvis et al, 1999; Wolff et 
al, 2005; Hieronymous et al, 2006).  Consequent reductions in plasma 
methadone levels over the course of pregnancy may put women at risk of 
relapse of illicit drug use. 
 
4.10.1  The maternal methadone dose should be individually adjusted to control 
maternal craving or withdrawal symptoms. 
4.10.2 Adequacy of the maternal methadone dose should be reassessed at 
regular intervals during pregnancy. An inadequate methadone dose 
may result in subtle signs and symptoms of opioid withdrawal and lead 
to fetal stress and increased likelihood of maternal illicit drug use. 
4.10.3   Pharmacokinetic changes in pregnancy may lead to the need for higher 
methadone doses to achieve consistent plasma methadone levels, 
particularly in the third trimester. 
4.10.4  Withdrawal from methadone is not recommended during pregnancy due 
to high relapse rates and the risks associated with resumption of 
maternal illicit drug use. 
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5. Hospital Equipment and Facilities 
Point of care urine toxicology testing strips are required in all maternity units to 
allow objective assessment of maternal methadone or illicit opioid use. 
6. Implementation Strategy 
 Distribution of guideline to all members of the Institute and to all maternity 
hospitals. 
 Implementation through HSE Obstetrics and Gynaecology programme local 
implementation boards. 
 Distribution to other interested parties and professional bodies. 
7. Key Performance Indicators 
To be developed.  
8. Qualifying Statement  
This guideline has been prepared to promote and facilitate standardisation and 
consistency of practice, using a multidisciplinary approach. Clinical material 
offered in this guideline does not replace or remove clinical judgement or the 
professional care and duty necessary for each pregnant woman. Clinical care 
carried out in accordance with this guideline should be provided within the 
context of locally available resources and expertise. 
 
This Guideline does not address all elements of standard practice and assumes 
that individual clinicians are responsible for:  
 
 Discussing care with women in an environment that is appropriate and which 
enables respectful confidential discussion.  
 Advising women of their choices and ensure informed consent is obtained.  
 Meeting all legislative requirements and maintaining standards of 
professional conduct.  
 Applying standard precautions and additional precautions, as necessary, 
when delivering care 
 Documenting all care in accordance with local and mandatory requirements. 
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9. Appendices 
Appendix 1- Treatment of Suspected Opiate Overdose 
 
 Anaesthetic staff should be consulted at the earliest opportunity. 
 
 Assess the patient for respiratory depression- if the respiratory rate is 
less than 12 breaths per minute consider the need for naloxone. 
 
 CAUTION! Naloxone will precipitate acute opiate withdrawal 
which may lead to preterm labour. 
 
 Naloxone is the treatment of choice for the reversal of coma and the 
restoration of spontaneous respiration. 
 
 In opioid-dependent patients the administration of the recommended 
dose of an opioid antagonist may precipitate an acute withdrawal 
syndrome. The severity will depend on the degree of physical 
dependence and the dose of naloxone administered.  
 
 If the patient is unresponsive, a bolus dose of naloxone should be 
administered. Naloxone is available as a 0.4mg/mL injection. It is 
administered by intravenous injection of 0.4–2mg; if no response- 
repeat at intervals of 2–3 minutes to a maximum of 10mg (then review 
diagnosis). (BNF 60) 
 
 If the patient is responsive, but has severe respiratory depression 
(respiratory rate < 8 breaths/minute) naloxone should be administered 
with extreme care and by titration with smaller than usual doses of 
naloxone (give 100-200 micrograms; if response inadequate, give 
subsequent doses of 100 micrograms every 2 minutes. (BNF 60) 
 
 Further doses of naloxone may be required if respiratory function 
deteriorates. Naloxone has a short duration of action (repeated doses 
or infusion may be necessary to reverse effects of opioids with longer 
duration of action) (BNF 60). 
 
 Consider benzodiazepine toxicity, seek advice expert advice from the 
Poisons Information Centre of Ireland (01 8379964 or 8092566) before 
the use of flumazenil (BNF 60). 
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Appendix 2 - Inpatient Methadone Record Sheet 
 
Dispensing Clinic/Pharmacy:_____________________________ 
Phone: _____________________________  
Fax: _____________________________ 
Patient Sticker here 
Prescriber: _____________________________ 
Phone: _____________________________ 
Fax: _____________________________ 
 
 
On each admission: methadone dose confirmed/pharmacy notified of 
admission:     
Date Methadone Dose Confirmed with Signature 
    
    
    
    
    
 
On discharge: Pharmacy/Prescriber informed of methadone dispensed 
and any opioids administered as an inpatient:  
Date Confirmed with Signature 
   
   
   
   
   
 
“Take away” methadone returned to pharmacy for destruction:   
Date Amount  Midwife/Nurse 
Signature 
Pharmacist 
Signature 
Date 
     
     
     
CLINICAL PRACTICE GUIDELINE          METHADONE PRESCRIBING AND ADMINISTRATION IN 
PREGNANCY 
 
 20 
Appendix 3 - Clinical Opiate Withdrawal Scale 
 
For each item, circle the number that best describes the patient‘s signs or 
symptom.  Rate on just the apparent relationship to opiate withdrawal.  For 
example, if heart rate is increased because the patient was jogging just prior to 
assessment, the increase pulse rate would not add to the score. 
 
Patient‟s Name:___________________   
Date and Time ___/_____/____:__________ 
Reason for this assessment:______________________________ 
Resting Pulse Rate:                     
_________beats/minute 
Measured after patient is sitting or lying for one 
minute  
0 pulse rate 80 or below 
1 pulse rate 81-100 
2 pulse rate 101-120 
4 pulse rate greater than 120 
GI Upset: over last ½ hour 
0 no GI symptoms 
1 stomach cramps 
2 nausea or loose stool 
3 vomiting or diarrhea 
5 Multiple episodes of diarrhea or vomiting 
Sweating: over past ½ hour not accounted for by 
room temperature or patient activity. 
0 no report of chills or flushing 
1 subjective report of chills or flushing 
2 flushed or observable moistness on face 
3 beads of sweat on brow or face 
4 sweat streaming off face 
Tremor observation of outstretched hands 
0 No tremor 
1 tremor can be felt, but not observed 
2 slight tremor observable 
4 gross tremor or muscle twitching 
 
Restlessness Observation during assessment 
0 able to sit still 
1 reports difficulty sitting still, but is able to do so 
3 frequent shifting or extraneous movements of 
legs/arms 
5 Unable to sit still for more than a few seconds 
Yawning Observation during assessment 
0 no yawning 
1 yawning once or twice during assessment 
2 yawning three or more times during 
assessment 
4 yawning several times/minute 
Pupil size 
0 pupils pinned or normal size for room light 
1 pupils possibly larger than normal for room light 
2 pupils moderately dilated 
5 pupils so dilated that only the rim of the iris is 
visible 
Anxiety or Irritability 
0 none 
1 patient reports increasing irritability or 
anxiousness 
2 patient obviously irritable anxious 
4 patient so irritable or anxious that 
participation in the assessment is difficult 
Bone or Joint aches If patient was having pain 
previously, only the additional component 
attributed to opiates withdrawal is scored 
0 not present 
1 mild diffuse discomfort 
2 patient reports severe diffuse aching of joints/ 
muscles 
4 patient is rubbing joints or muscles and is unable 
to sit still because of discomfort 
Gooseflesh skin 
0 skin is smooth 
3 piloerrection of skin can be felt or hairs 
standing up on arms 
5 prominent piloerrection 
 
Runny nose or tearing Not accounted for by cold 
symptoms or allergies 
0 not present 
1 nasal stuffiness or unusually moist eyes 
2 nose running or tearing 
4 nose constantly running or tears streaming down 
cheeks  
Total Score  ________ 
The total score is the sum of all 11 
items 
 
Signature of person 
completing Assessment:            
______________ 
Score: 5-12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = 
severe withdrawal  
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Appendix 4- Addiction Services Contact Details 
To be completed locally by each maternity unit 
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